Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Single dose of NN-2211 restores beta-cell responsiveness in type 2 diabetes

July 30, 2003

Lipid-lowering effects described for YM-53601 in rodents

July 30, 2003

CPMP issues positive opinion for Bondronat for metastatic bone disease

July 29, 2003

New phase I trial to evaluate lipid-regulating agent ETC-1001

July 29, 2003

Biotech Holdings plans postmarketing study for Sucanon in Mexico

July 29, 2003

New benzisoxazole-based LXR agonists under study at Merck

July 29, 2003

Novel lipase inhibitors for obesity and diabetes in early development at OSI

July 28, 2003

GSK scientists prepare and test new cathepsin K inhibitors

July 25, 2003

Glucagon antagonists/inverse agonists in Novo Nordisk pipeline

July 25, 2003

Simultaneous use of repaglinide and gemfibrozil may increase risk of hypoglycemia

July 24, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...